ESG

InspireSemi schedules a key shareholder update as its Thunderbird I chip, built on RISC-V, aims to challenge NVIDIA and AMD in the AI accelerator market.

A five-year R&D effort culminates in a free resource library, offering tools to improve K-12 math by strengthening students' core cognitive skills.

Wolters Kluwer and Palantir lead in user-driven awards, reflecting a market demand for holistic, data-centric solutions beyond traditional finance.

The customizable browser now lets users track their environmental impact, offsetting 599 tonnes of CO2. Is this the future of sustainable tech?

A packed event for nannies in Georgetown reveals a major shift in childcare: caregivers are demanding professional recognition, community, and better standards.

Cities are trading 1970s-era tech for smart systems that slash emergency response times, improve safety, and even lower insurance rates for residents.

As AI adoption soars, PwC Canada introduces North America's first Big 4 certification for the ISO 42001 AI standard, aiming to close the trust gap.

New add-on tests from a single blood draw help oncologists avoid toxic chemo reactions and filter out false positives, aiming for safer, smarter cancer care.

An Irish innovator and a Japanese manufacturing giant team up to scale next-gen liquid cooling, promising a more efficient and sustainable digital future.

Global shocks are roiling fertilizer markets, creating a 'new normal' of price volatility. Can biological solutions offer farmers the stability they need?

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

A new survey shows most family firms expect a leadership change soon, but few are prepared, creating a high-stakes gap between intent and action.

Celularity Inc. has secured a $12.2M cash injection by selling tax losses, a move set to accelerate its cutting-edge longevity and regenerative medicine pipeline.

Kincell Bio and RegCell partner to bring a groundbreaking, non-gene-edited Treg cell therapy for autoimmune diseases from the lab to clinical trials.

With a new CEO and stunning clinical data, BOOST Pharma advances a potential game-changer for children with the rare genetic disorder Osteogenesis Imperfecta.

Commercial real estate values rose for a sixth straight quarter, yet a stark divide between thriving industrial and lagging office sectors redefines the market.

Aardvark Therapeutics is expanding its Phase 3 trial for a novel Prader-Willi Syndrome drug to include children as young as seven, targeting a key unmet need.

Lithuanian manufacturer Eurodita's 'no minimum order' private-label plan could reshape Europe's construction market for independent dealers.

Ahead of its first Climate Week, Mumbai's food innovators and activists gather to debate a sustainable future, proving the fight for the planet begins on our plates.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.